# ELECTRA (NCT05386108)

> Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05386108
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Stemline Therapeutics, Inc.
- Conditions: Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases
- Interventions: Elacestrant; Abemaciclib
- Enrollment: 73
- Primary outcome: Phase 1b: RP2D
- Primary outcome: Phase 2: Objective Response Rate (ORR) Per Overall Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 7
- Podcasts: 6
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=electra-nct05386108

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05386108", "email": "<work email>"}; the inbox owner confirms by the emailed link.